<DOC>
	<DOCNO>NCT00673868</DOCNO>
	<brief_summary>This study examine immunologic virologic effect prophylactic CMV specific CTL recipient T cell deplete stem cell transplant ( TCD SCT ) Duke University Medical Center ( DUMC ) , measure level CMV DNA virus specific T cell precursor intervals post-infusion .</brief_summary>
	<brief_title>Cytomegalovirus ( CMV ) Specific Cytotoxic T Lymphocytes ( CTL ) When Used Prophylaxis Against CMV Recipients Allogeneic , T Cell Depleted Stem Cell Transplants</brief_title>
	<detailed_description>Human cytomegalovirus ( CMV ) benign infectious agent normal host , immunocompromised individual , recipient stem cell organ transplant , virus major cause morbidity mortality . While pharmacologic agent exist treat CMV disease , medication numerous side effect , serious myelosuppression . Considering risk associate persistent infection potential CMV specific CTL restore immunity , propose study immunologic virologic effect CMV pp65 specific CTL give SCT recipient prophylactically , level CMV pp65 specific CTL CMV DNA measure CTL recipient control group randomize receive CTL . All treatment give Duke University Medical Center ( DUMC ) . 1 . Patients complete set vital sign physical examination prior infusion . Pulse oximetry monitor prior , , 30 minute T-cell infusion . Thirty minute prior CTL infusion , patient pre-medicated 15 mg/kg ( maximum 1 g ) acetaminophen p.o . 1.0 mg/kg diphenhydramine I.V . ( maximum 50 mg ) . Cells thaw Cell Therapy lab DUMC , aliquot send gram stain culture , viability determine . Cells &gt; 70 % viability transfer clinical unit infuse 5-10 minute . 2 . CMV CTL infuse available day 30 40 post-transplant dose range 2- 5 x 105 cells/kg . This dose range establish since may variability number CTL expand donor .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Any allogeneic stem cell transplant recipient &gt; 2 year age CMV seropositive CMV seropositive donor , Bilirubin &lt; 2.0 mg/dl ; SGOT/SGPT &lt; 2.5 X normal . Creatinine clearance &gt; 50 cc/min estimate patient 's serum creatinine , weight , age . Pulse oximetry &gt; 95 % supplemental oxygen . ECOG performance status &lt; 2 ; patient , 16 year age , Lansky performance status &gt; 70 % . Seronegative patient history GVHD grade II great Glucksberg crireria ( protocol Appendix I ) prior day +30 current stem cell transplant exclude . Patients receive prior stem cell transplant exclude . Patients moribund cardiac , pulmonary , renal , hepatic neurologic dysfunction expect survive one month . Subjects receive systemic immunosuppressive agent treatment GVHD time CTL infusion exclude receive CTL , subject randomize receive CTL also remove study time CTL infusion require systemic immunosuppression treatment GVHD Donors must negative HIV1 , HIV2 , HTLV2 , pass screening test hepatitis .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>